key: cord-0717654-z56xqis1 authors: Jeckelmann, Clarisse; Djokic, Bojan; Duchatelle, Valérie; Girod, Grégoire title: Case report: Mechanical mitral prosthetic valve thrombosis in the context of COVID-19 despite effective anticoagulation date: 2022-01-24 journal: Eur Heart J Case Rep DOI: 10.1093/ehjcr/ytac006 sha: c659862f233763f8adcef655b495eae9015761d5 doc_id: 717654 cord_uid: z56xqis1 BACKGROUND: The SARS-CoV2 virus has been an emerging virus since December 2019 and is the cause of a global pandemic whose clinical manifestations extend far beyond respiratory disease. CASE SUMMARY: A patient with severe COVID 19 respiratory infection, carrying a mechanical mitral valve and under anticoagulation, was admitted in our cardiology department because of a new atrial fibrillation, which turned out to be related to thrombosis of the mitral mechanical valve. CONCLUSION: The pro-coagulant effect of the SARS-CoV2 virus does not spare patients at risk of thrombosis, even under effective anticoagulation. In patients with mechanical valves under vitamin K antagonist treatment, there is a high risk of thrombus formation. The treatment is based on thrombolysis by therapeutic anticoagulation, fibrinolysis or surgery depending on the size, composition of thrombus and clinical manifestation. Since the beginning of the SARS-CoV-2 pandemic, which began at the end of 2019, numerous studies have reported a wide range of different clinical manifestations of this pathology, including a hypercoagulable state. This complication can affect up to a third of intensive care patients 5 . This observation raises the question of anticoagulation, in both, patients without prior anticoagulation and particularly previously anticoagulated patients, whose data and recommendations in this context are very limited. The following clinical case report describes a patient with a mechanical mitral valve on adequate acenocoumarol treatment with severe SARS-CoV-2 infection. We report the discussion regarding the diagnostic and therapeutic management of a heart valve thrombus in the setting of SARS-CoV 2 infection and the need or not for change in anticoagulation therapy in this context. A 58-year-old female was admitted in the intensive care unit with severe hypoxemic respiratory failure caused by the SARS-CoV-2 infection. She had been implanted six years ago with a Medical Medtronic ATS 27 mm mechanical mitral valve for severe mitral stenosis and was treated with acenocoumarol. INR over the past three months was mostly in therapeutic range of 2.5 to 3.5 6 . Upon admission, she presented new onset atrial fibrillation (AF). Laboratory results showed electrolytes in normal range, normal renal and liver function. Troponin T hs was 16 ng/l (n<14 ng/l), NT pro-BNP 3'146 ng/l (n<300 ng/l), D-dimers 6'893 mcg/l (n<350 mcg/l), INR 2.7. The thoracic CTscan ( Figure 1 ) showed typical alveolar COVID-19 lesions, indirect signs of pulmonary hypertension (PH) (dilated pulmonary artery) without pulmonary embolism, and a massively dilated left atrium (LA). Because of the critical patient's condition, initial treatment upon admission included mechanical ventilation, discontinuation of VKA treatment in the benefit of enoxaparin (80mg 2x/d SQ). The respiratory state quickly improved allowing the patient to be transferred to the cardiology department for further investigation regarding the new onset AF. Upon arrival in the cardiology department, clinical findings included: HR 125 bpm, BP 103/65mmHg, pulse oximetry 95% with 2L/min nasal oxygen therapy, irregular heartbeats, normal mechanical valve clicks, and a diastolic murmur and bilateral pulmonary crackles. The neurological status was normal. A transthoracic echocardiography ( Figure 2 ) showed reduced mobility of the two leaflets of the mechanical mitral prosthesis with an image suggestive of thrombus. Transprothetic mitral Doppler peak velocity was elevated (254 cm/s ), pressure half time was prolonged (213 ms). The mean transprosthetic gradient (TPG) was 16 mmHg. The LA was severely dilated (90ml -59 ml/m 2 ). Pulmonary hypertension was likely (tricuspid insufficiency speed 341 cm/s and interventricular septal D-shaping) with an estimated pulmonary arterial pressure (PAP) of 57/32-39 (s/d-mean) mmHg. Left ventricular ejection fraction was 55%. Initial fluorography of the mechanical valve ( Figure 3 ) showed complete immobility of one of the leaflets and hypo-mobility of the other. A transesophageal ultrasound (Figure 4) showed the presence of a 9x6 mm hypoechogenic mass attached to one of the leaflets. At this point, differential diagnosis were obstructive valve thrombosis or infectious endocarditis. Given the context and the negative blood cultures, infectious endocarditis was unlikely. Therapeutic anticoagulation by intravenous (IV) heparin was initiated to treat the suspected valve thrombosis. However, a control valve fluorography performed after one week did not show any improvements in leaflets mobility. Therefore, low dose IV thrombolysis alteplase (rtPA) was administered (10 mg bolus followed by 1. A rate control strategy was chosen for AF management using betablockers and digoxin. The clinical course was favorable, and the patient was discharged home a week later. At one year follow up, a transthoracic echocardiogram showed a TPG of 4mmHg, mitral valve area of 4.25cm2 and PAP estimated at 26mmHg. Asymptomatic permanent AF at 72bpm was diagnosed. The present case reports a mechanical mitral valve thrombosis, despite adequate anticoagulation in a patient with acute severe SARS-CoV-2 infection. The pathophysiology of hypercoagulability linked to this virus is currently unclear. Recent studies suggest the role of a large cascade of pro-inflammatory cytokines and interleukins resulting in a pro-thrombotic state 7 . This prothrombotic state is suspected to cause both arterial and venous thrombosis. Several publications 8 have reported pulmonary embolism, deep venous thrombosis or acute coronary syndromes in SARS-CoV-2 patients. This case is, to our knowledge, the first report of mitral mechanical valve thrombosis in a SARS-CoV-2 patient. This case addresses the problem of abnormal mechanical valve function in a SARS-CoV-2 patient despite therapeutic anticoagulation. The presence of an elevated TPG and an hypoechogenic mass attached to the leaflets on the TTE was compatible with valve thrombosis, infectious endocarditis, or pannus (peri-annular fibrous outgrowth) (less likely). Since no biological or imaging testing is pathognomonic of any of these three hypothesis, a careful rule-out strategy should be performed. Peri-annular fibrous outgrowth, or pannus, is a chronic slowly progressive disease and seemed unlikely to account for an acute valve dysfunction. Furthermore, obstructive pannus is a more common complication of aortic valve prosthesis than mitral. Its typical echocardiographic aspect is hyperechogenic 9 which differs from our echographic findings in this case. Regarding the possibility of infectious endocarditis, in the presence of repeated negative blood cultures and resolution of clinical and biological signs of infection after SARS-CoV2, we ruled out this differential diagnosis. Therefore, mechanical valve thrombosis seemed to be the most likely diagnosis. The most frequent cause of mechanical valve thrombosis is non-optimal anticoagulation in 45% of cases according to a cohort study from the Montreal Institute 10 . Therapeutic anticoagulation with VKA is defined by an INR within the therapeutic more than 70% of time, according to European society of Cardiology guidelines for atrial fibrillation 11 , otherwise no specific time in After taking account all the previous considerations, we found valve thrombosis in this patient to be unlikely related to a lack of anticoagulation (or at least not alone). Therefore, we investigated the potential role of the SRAS-CoV-2 infection in this matter. In This clinical case raises the question of a possible SARS-CoV-2 related risk of valve thrombosis due to a pro thrombotic state or VKA resistance. In SARS-CoV-2 patients, only one case of bioprosthetic mitral valve thrombosis 17 and one case of aortic mechanical valve thrombosis 18 have been published. Surgery is the therapeutic option of choice in case of non-obstructive mechanical prosthetic valve thrombosis (PVT) and if the thrombus is more than 10mm, complicated by emboli or/and refractory to anticoagulation 19 . If the operative risk is too high, thrombolysis is the preferred therapy 20 . Since the thrombosis was obstructive but well tolerated, a conservative treatment was chosen, considering patient's fragility and preference. Thrombolysis was incompletely successful (according to decreased gradient on TOE, and improved, but not complete, mobility of leaflets), suggesting a mixed component obstruction (pannus and thrombus) whose acute deterioration would be due to a thrombus. Mechanical valve thrombosis, regardless of its severity is associated with poor short-and long-term outcome 21 . Therefore, should anticoagulation treatment be reinforced in SRAS COV 2 patients to prevent valve thrombosis? Would an increase in the usual doses be sufficient, or would a change of the molecule be necessary? Should aspirin be added to VKA? Further studies will be necessary to answer these questions. Patients implanted with mechanical valve prosthesis should benefit from therapeutic anticoagulation with VKA for life, with close INR monitoring in order to avoid thrombosis of the prosthesis. This article reports a case of mechanical mitral PVT, despite therapeutic INR, in a critically ill SARS-CoV-2 patient. The PVT was successfully treated by intravenous thrombolysis with rTPA. We suspect an implication of the SARS-CoV-2 virus in the PVT, although the mechanisms are unclear. The SARS-CoV-2 pro inflammatory and pro coagulant states may have played a part in the PVT. Further observations will be needed to confirm the suspected increase of PVT risk during SARS-CoV-2 infection, as well as the best preventive and curative strategies. Supplementary material is available at European Heart Journal-Case reports online. Slide sets: an edited slide set detailing this case and suitable for presentation is available as supplementary data. Consent: The authors confirm that witnessed verbal consent for submission and publication of this case report including images and associated text has been obtained from the patients detailed in this case report. This has been discussed with the editors. Learning points  The incidence of thrombo-embolic events may increase during COVID-19 pandemic, due to the procoagulant state induced by severe acute respiratory syndrome coronavirus 2 infection.  Carriers of mechanical heart valves are at risk of valve thrombosis in the clinical setting of COVID-19 infection.  Standardized prophylactic anticoagulation protocols for inpatient and outpatient settings are needed due to the high risk of thromboembolic events in COVID-19 patients. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability Mayo clinic's referrals . Prosthetic valve thrombosis: Time is critical Coagulopathy in COVID-19 Clinical spectrum of ischaemic arterial diseases associated with COVID-19: a series of four illustrative cases A global perspective on mechanical prosthetic heart valve thrombosis: Diagnostic and therapeutic challenges Prosthetic valve thrombosis: twenty-year experience at the montreal heart institute ESC Guidelines for the diagnosis and management of atrial fibrillation Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology 15 National Health Institute. COVID-19 Treatment Guidelines Panel Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19 Mechanical Aortic Prosthetic Thrombosis in a 65-Year-Old Woman with SARS-CoV-2 Infection Thrombosis of prosthetic heart valves : diagnosis and therapeuthic consideration Clinical Practice Guidelines for the managment of Valvular Heart Disease Mechanical cardiac valve thrombosis in patients in critical hemodynamic compromise